Panel Discussion: Overcoming the Phase 2/3 Roadblock in Neuropsychiatric Drug Development: What Have We Learnt in 2026?
8:00 am - Wednesday 16th September 2026
- What recent Phase 2 and Phase 3 readouts have taught us about target validation in neuropsychiatric drug development?
- How can sponsors better address persistent challenges around placebo response, site quality and trial execution?
- To what extent do indication selection and patient population definitions influence the probability of success?
- How can biomarkers, precision psychiatry approaches and improved patient stratification help derisk future development programmes?
- What lessons from recent successes and setbacks should shape the next generation of neuropsychiatric clinical trials?
